<div class="xtend">
         <div class="xtend_ce"><a id="pl.1.1"></a><var>1.1</var>A bill for an act<br />
            		
         </div><a id="pl.1.2"></a><var>1.2</var>relating to insurance; requiring health plans to establish equal out-of-pocket <br />
         		<a id="pl.1.3"></a><var>1.3</var>requirements for oral chemotherapy medications and intravenously administered <br />
         		<a id="pl.1.4"></a><var>1.4</var>chemotherapy medications;proposing coding for new law in Minnesota Statutes, <br />
         		<a id="pl.1.5"></a><var>1.5</var>chapter 62A.<br />
         		<a id="pl.1.6"></a><var>1.6</var>BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:<br />
         		<br />
         		<a id="bill.0.1.0"></a><a id="pl.1.7"></a><var>1.7</var>&nbsp;&nbsp;&nbsp;&nbsp;Section 1. <b>[62A.3075] CANCER CHEMOTHERAPY TREATMENT </b><br />
         		<a id="pl.1.8"></a><var>1.8</var><b>COVERAGE.</b><br />
         		<a id="pl.1.9"></a><var>1.9</var>(a) A health plan company that provides coverage under a health plan for cancer <br />
         		<a id="pl.1.10"></a><var>1.10</var>chemotherapy treatment shall not require a higher co-payment, deductible, or coinsurance <br />
         		<a id="pl.1.11"></a><var>1.11</var>amount for a prescribed, orally administered anticancer medication that is used to kill or <br />
         		<a id="pl.1.12"></a><var>1.12</var>slow the growth of cancerous cells than what the health plan requires for an intravenously <br />
         		<a id="pl.1.13"></a><var>1.13</var>administered or injected cancer medication that is provided, regardless of formulation or <br />
         		<a id="pl.1.14"></a><var>1.14</var>benefit category determination by the health plan company.<br />
         		<a id="pl.1.15"></a><var>1.15</var>(b) A health plan company must not achieve compliance with this section <br />
         		<a id="pl.1.16"></a><var>1.16</var>by imposing an increase in co-payment, deductible, or coinsurance amount for an <br />
         		<a id="pl.1.17"></a><var>1.17</var>intravenously administered or injected cancer chemotherapy agent covered under the <br />
         		<a id="pl.1.18"></a><var>1.18</var>health plan.<br />
         		<a id="pl.1.19"></a><var>1.19</var>(c) Nothing in this section shall be interpreted to prohibit a health plan company <br />
         		<a id="pl.1.20"></a><var>1.20</var>from requiring prior authorization or imposing other appropriate utilization controls in <br />
         		<a id="pl.1.21"></a><var>1.21</var>approving coverage for any chemotherapy.<br />
         		<a id="pl.1.22"></a><var>1.22</var>(d) A plan offered by the commissioner of management and budget under section <br />
         		<a id="pl.1.23"></a><var>1.23</var>43A.23 is deemed to be at parity and in compliance with this section.<br />
         		<a id="pl.1.24"></a><var>1.24</var>(e) A health plan company is in compliance with this section if it does not include <br />
         		<a id="pl.1.25"></a><var>1.25</var>orally administered anticancer medication in the fourth tier of its pharmacy benefit.<br />
         		<a id="pl.2.1"></a><var>2.1</var><b>EFFECTIVE DATE.</b>Paragraphs (a) and (c) are effective August 1, 2010, and apply <br />
         		<a id="pl.2.2"></a><var>2.2</var>to health plans providing coverage to a Minnesota resident offered, issued, sold, renewed, <br />
         		<a id="pl.2.3"></a><var>2.3</var>or continued as defined in Minnesota Statutes, section 60A.02, subdivision 2a, on or after <br />
         		<a id="pl.2.4"></a><var>2.4</var>that date. Paragraph (b) is effective the day following final enactment.<br />
         		
      </div>